Tom Frohlich is COO of Chinook Therapeutics. He co-founded and joined Chinook in January 2019. Previously, he served as entrepreneur-in-residence at Versant Ventures. From 2014 to 2018, Frohlich was vice-president of business development at Arbutus Biopharma, and prior to that, he spent more than 12 years at Johnson & Johnson and Merck.
BEVERAGE OF CHOICE: “Coffee, for sure! The first purchase after we raised our $65 million Series A financing at Chinook was an amazing espresso maker for the kitchen area of our labs.” GREATEST SUCCESS: “It has been a thrill to help the company grow from a small handful of employees at launch in 2019 to now being a Nasdaq-listed company with a robust pipeline of experimental drugs and a staff of over 115 highly talented individuals.”